Skip to main content
BioLineRx Ltd. logo

BioLineRx Ltd. — Investor Relations & Filings

Ticker · BLRX ISIN · US09071M2052 LEI · 529900AKIOSC15Y63R18 TA Manufacturing
Open in API
Filings indexed 1,673 across all filing types
Latest filing 2024-08-19 Proxy Solicitation & In…
Country IL Israel
Listing TA BLRX

About BioLineRx Ltd.

https://www.biolinerx.com/

BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for oncology and rare diseases. The company leverages its drug development capabilities to advance novel, early-stage therapeutic candidates through the clinical development process toward regulatory approval. Its pipeline consists of treatments, including small molecules, designed to address unmet medical needs and deliver meaningful benefits to patients. BioLineRx also partners with other drug developers to advance their early-stage programs.

Recent filings

Filing Released Lang Actions
Immediate Report of Meeting to be held on October 1, 2024,proxy statement
Proxy Solicitation & Information Statement Classification · 100% confidence The document explicitly states it is a 'PROXY' solicited on behalf of the Board of Directors for the 'Annual General Meeting of Shareholders to be held on October 1, 2024'. It details the appointment of proxies and lists specific resolutions to be voted upon at the AGM, such as the re-election of directors and approval of auditor reappointment. This content is characteristic of proxy materials used to solicit shareholder votes for an AGM, which aligns directly with the definition of Proxy Solicitation & Information Statement (DEF 14A in US context, but based on the provided definitions, it is most closely related to soliciting votes for the AGM). However, the definition for AGM-R is 'Presentations and materials shared during the Annual General Meeting (AGM)'. The definition for PSI is 'Proxy Solicitation & Information Statement'. Since this document is the actual proxy card/form used to solicit votes *before* the meeting, PSI (Proxy Solicitation & Information Statement) is the most precise fit, although AGM-R is also highly relevant as it pertains to the AGM. Given the structure as a formal proxy card requesting votes on specific proposals, PSI is the superior classification over AGM-R (which implies materials *used* during the meeting, like slides).
2024-08-19 English
Immediate Report of Meeting to be held on October 1, 2024,proxy statement
AGM Information Classification · 98% confidence The document is explicitly titled 'FORM 6-K' and is a 'REPORT OF FOREIGN PRIVATE ISSUER'. However, the content primarily consists of the 'NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS' and the 'PROXY STATEMENT' for a meeting scheduled for October 1, 2024. The Form 6-K is being used as the filing vehicle to submit these materials (Exhibit 99.1, 99.2, 99.3) to the SEC. The core subject matter being distributed to shareholders is the notice and proxy materials for the Annual General Meeting. According to the definitions, materials shared during the AGM or related to soliciting votes for it fall under AGM Information (AGM-R) or Proxy Solicitation & Information Statement (PSI). Since the document is the Proxy Statement and Notice soliciting votes for the upcoming AGM, PSI is highly relevant, but AGM-R covers the general meeting materials. Given the explicit mention of 'Notice of Annual General Meeting of Shareholders' and the detailed proxy solicitation instructions, AGM-R (AGM Information) is the most fitting primary classification for the substance being delivered, as the proxy statement is the key document for the AGM. PSI is also very close, but AGM-R captures the event itself.
2024-08-19 English
Immediate Report of Meeting to be held on October 1, 2024,proxy statement
AGM Information Classification · 98% confidence The document explicitly states that the corporation is giving notice of the 'convening of meeting' for a 'general meeting' scheduled for 01/10/2024. The agenda items primarily concern the re-election of directors and the reappointment of auditors, which are standard items for an Annual General Meeting (AGM). Although it mentions an attachment ('FORM_6-K_19-Aug-2024_isa.pdf'), the core purpose of this filing is to announce the details and agenda for the upcoming shareholder meeting, making it an AGM-related document, specifically the notice/announcement itself. This aligns best with the AGM Information (AGM-R) category, which covers presentations and materials shared during the AGM, and by extension, the notice convening it.
2024-08-19 English
6-K
Regulatory Filings
2024-08-19 English
6-K
Regulatory Filings
2024-08-15 English
Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
Interim / Quarterly Report Classification · 100% confidence The document is a Form 6-K filed with the SEC by BioLineRx Ltd. It contains the company's unaudited financial results for the three and six months ended June 30, 2024, including a detailed breakdown of revenue, expenses, and net income, as well as operational updates. Because it provides substantive financial data and analysis for an interim period, it is classified as an Interim/Quarterly Report (IR). Q2 2024
2024-08-15 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.